arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Valion Bio, Inc.

VBIO

$0.28 ▲ +0.02 (+6.53%) at close

6 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Valion Bio, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -182.8% ↘

FCF / Share $-6.09 ↗

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.18M

↓ -36.1% —

Net Income Profit after all expenses

$-8.88M

↓ -57.0% —

FCF / Share Free cash flow per share

$-6.09

↑ +69.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	—	—	-36.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-551%)	46.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+480%)	—	—
EPS Growth YoY (%)	60.2% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	88.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	90.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	57.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-57.0% Weak ↓ Weak Declining Year-over-year change in net income	31.4% Excellent ↑ Excellent Improving Year-over-year change in net income	18.3% Good Good Year-over-year change in net income	-18.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	69.4% Excellent Excellent Year-over-year change in free cash flow	89.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Operating Margin (%) (%)	—	—	—	—	-448.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3088%)	—
FCF Margin (%) (%)	—	—	—	-485.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-446.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.79x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-182.8% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-139.5% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-181.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-219.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-33.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-25.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-159.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-159.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-171.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-37.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-260.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1834%)	-223.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1587%)	-230.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1635%)	-278.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1954%)	-64.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-527%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Interest Coverage (x)	—	—	—	—	-3.09x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-12.64M	$-2.00M	$-3.40M	$-3.52M	$-12.97M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	—	—	$25.22	—	$611.96	—
Basic EPS, GAAP (USD)	$-7.84	$-19.68	$-176.87	$-1.77K	$-4.13K	—
Free Cash Flow per Share (USD)	$-6.09	$-19.92	$-185.05	—	—	—
Book Value per Share (USD)	$1.35	$4.55	$41.53	—	$2.32K	—
Tangible Book Value per Share (USD)	$-0.91	$4.55	$41.53	—	$2.32K	—
Basic Weighted Avg Shares (shares)	1.16M	287,370	46,631	5,691	2,054	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$12.36M	$2.37M	$3.25M	$3.43M	$13.07M	—
Total Equity (USD)	$3.41M	$2.54M	$3.58M	$3.63M	$13.27M	$-1.18M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	$1.18M	$1.84M	$1.26M	—
Depreciation Expense (USD)	$5.00K	$3.00K	$8.00K	$10.00K	$8.00K	—
Net Income, GAAP (USD)	$-8.88M	$-5.66M	$-8.24M	$-10.10M	$-8.49M	—
Operating Cash Flow (USD)	$-7.00M	$-5.72M	$-8.51M	$-8.92M	$-5.61M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters

Valion Bio, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare VBIO with peers